Albemarle Corporation (ALB)

NYSE Materials Specialty Chemicals S&P 500
$99.25
+0.88 (+0.89%)
Close of Nov 06, 2026 · end-of-day data
Next earnings date
Not scheduled yet
No report date announced in the next three weeks.
Consensus EPS estimate
—
Shown once a date is announced.
Last report (Nov 04)
$2.58 vs $2.56 est.
Surprise +0.8%

Earnings surprise history

reported EPS vs consensus
ReportedQuarterEPS estimateReported EPSSurprise
Nov 04, 2026Sep/2026$2.56$2.58+0.8%

Our record of ALB's reports since we began tracking; it grows each quarter.

Latest results, in brief

All ALB 8-K briefs →
Nov 4, 4:19 PM ET

Albemarle Q3 net sales rise 19% to $1.6 billion; Specialties outlook raised

Positive earnings 2.02

Albemarle reported third-quarter 2026 net sales of $1.6 billion, up 19% from a year earlier, and net income attributable to the company of $297 million, or $2.15 per diluted share, compared with a loss of $1.72 per share in the prior-year quarter. The company raised its full-year 2026 Specialties adjusted EBITDA outlook to $350-$375 million and cut its capital expenditure forecast to $300-$350 million, but said fourth-quarter net sales and adjusted EBITDA are expected to decline sequentially on lower lithium market pricing.

  • Q3 2026 net sales were $1,553.1 million, up 18.8% from $1,307.8 million in Q3 2025; adjusted EBITDA was $645.5 million, up 186.1%.
  • Diluted EPS was $2.15; adjusted diluted EPS was $2.58, compared with an adjusted loss of $0.19 in Q3 2025.
  • Full-year 2026 Specialties adjusted EBITDA outlook was raised to $350-$375 million from $275-$325 million.
  • Full-year 2026 capital expenditure forecast was reduced to $300-$350 million from approximately $500 million; Q4 2026 net sales and adjusted EBITDA are expected to decrease sequentially.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Quarter endedRevenueYoYEPS (diluted)YoYNet incomeNet margin
Sep 2026$1.55B+18.8% $2.15— $296.75M19.1%
Jun 2026$1.74B+31.1% $3.52— $479.96M27.5%
Mar 2026$1.43B+32.7% $2.34— $319.09M22.3%
Dec 2025$1.43B+15.9% $-3.88-1437.9% -$414.18M-29.0%
Sep 2025$1.31B-3.5% $-1.72— -$160.69M-12.3%
Jun 2025$1.33B-7.0% $-0.16— $22.90M1.7%
Mar 2025$1.08B-20.9% $0.00— $41.35M3.8%
Dec 2024$1.23B-47.7% $0.29— $75.29M6.1%

From Albemarle Corporation's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.

Annual results

Fiscal yearRevenueGrowthEPS (diluted)GrowthNet margin
FY2025$5.14B-4.4% $-5.76—-9.9%
FY2024$5.38B-44.1% $-11.20-183.8%-21.9%
FY2023$9.62B+31.4% $13.36-41.5%16.4%
FY2022$7.32B+120.0% $22.84+2054.7%36.7%
FY2021$3.33B+6.4% $1.06-69.9%3.7%

Frequently asked questions

When is Albemarle's next earnings date?

Albemarle has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.

What did Albemarle earn last quarter?

For the quarter ended Sep 2026, Albemarle reported diluted EPS of $2.15 on revenue of $1.55B (+18.8%).

Where do these numbers come from?

Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.

Not investment advice. Figures can be restated by the company in later filings.